Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2017

  • ID: 4375965
  • Report
  • 97 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • BioControl Medical
  • CerboMed GmbH
  • Cyberonics Inc
  • ElectroCore, LLC
  • MicroTransponder Inc
  • Purdue University
  • MORE
Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2017

Summary

The author's Medical Devices sector report, “Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2017" provides an overview of Vagus Nerve Stimulators currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vagus Nerve Stimulators pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Vagus Nerve Stimulators under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Vagus Nerve Stimulators and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Vagus Nerve Stimulators under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BioControl Medical
  • CerboMed GmbH
  • Cyberonics Inc
  • ElectroCore, LLC
  • MicroTransponder Inc
  • Purdue University
  • MORE
1 Table of Contents
2 Introduction
2.1 Vagus Nerve Stimulators Overview
3 Products under Development
3.1 Vagus Nerve Stimulators - Pipeline Products by Stage of Development
3.2 Vagus Nerve Stimulators - Pipeline Products by Territory
3.3 Vagus Nerve Stimulators - Pipeline Products by Regulatory Path
3.4 Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date
3.5 Vagus Nerve Stimulators - Ongoing Clinical Trials
4 Vagus Nerve Stimulators - Pipeline Products under Development by Companies
4.1 Vagus Nerve Stimulators Companies - Pipeline Products by Stage of Development
4.2 Vagus Nerve Stimulators - Pipeline Products by Stage of Development
5 Vagus Nerve Stimulators Companies and Product Overview
5.1 BioControl Medical Company Overview
5.1.1 BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview
5.2 Boston Scientific Corp Company Overview
5.2.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
5.3 CerboMed GmbH Company Overview
5.3.1 CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.4 Cerebral RX Ltd. Company Overview
5.4.1 Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.5 Cyberonics Inc Company Overview
5.5.1 Cyberonics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.6 DuoCure Ltd. Company Overview
5.6.1 DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.7 ElectroCore, LLC Company Overview
5.7.1 ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.8 LivaNova PLC Company Overview
5.8.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview
5.9 Medical University of South Carolina Company Overview
5.9.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview
5.10 MicroTransponder Inc Company Overview
5.10.1 MicroTransponder Inc Pipeline Products & Ongoing Clinical Trials Overview
5.11 Otto Bock HealthCare GmbH Company Overview
5.11.1 Otto Bock HealthCare GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.12 Purdue University Company Overview
5.12.1 Purdue University Pipeline Products & Ongoing Clinical Trials Overview
5.13 Setpoint Medical Corp Company Overview
5.13.1 Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
5.14 Trifectas Medical Corp. Company Overview
5.14.1 Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview
6 Vagus Nerve Stimulators- Recent Developments
6.1 Aug 01, 2017: VNS Therapy Receives CE Mark for Expanded MRI Labeling
6.2 Jul 31, 2017: SetPoint Medical Appoints Terry Bevirt as VP of Clinical Affairs
6.3 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017
6.4 Jul 18, 2017: GammaCore, The First Non-Invasive Vagus Nerve Stimulator Applied At The Neck, Now Available For Adult Patients In The U.S.
6.5 Jun 29, 2017: FDA Approves VNS Therapy Treatment for Drug-Resistant Epilepsy in Children as Young as Four Years Old
6.6 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day
6.7 Jun 21, 2017: VNS Therapy Receives FDA Approval for Expanded MRI Labeling
6.8 Jun 15, 2017: SetPoint Medical Appoints David Chernoff, MD as Chief Medical Officer
6.9 Jun 12, 2017: LivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel
6.10 Jun 08, 2017: New Analysis of ACT Clinical Trial Program Highlights Efficacy and Safety of electroCore’s gammaCore (non-invasive vagus nerve stimulator) in the Acute Treatment of Episodic Cluster Headache
6.11 May 30, 2017: MicroTransponder Presents Long Term Stroke Trial Data at INS and Announces a 120 Patient Pivotal Stroke Trial
6.12 May 16, 2017: LivaNova Announces Thad Huston as Chief Financial Officer
6.13 May 03, 2017: LivaNova Reports First Quarter 2017 Results
6.14 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017
6.15 Apr 26, 2017: electroCore Announces Data Presentation at the 69th American Academy of Neurology Annual Meeting
6.16 Apr 18, 2017: FDA Releases gammaCore, the First Non-Invasive Vagus Nerve Stimulation Therapy Applied at the Neck for Acute Treatment of Pain Associated with Episodic Cluster Headache in Adult Patients
6.17 Mar 31, 2017: New Study Finds Promising Treatment Option for Treatment-Resistant Depression
6.18 Mar 31, 2017: LivaNova Announces Chief Financial Officer Resignation
6.19 Mar 31, 2017: LivaNova Reiterates Full-Year 2017 Guidance
6.20 Mar 01, 2017: LivaNova Reports Fourth Quarter and Full-Year 2016 Results
6.21 Feb 28, 2017: Results for the second quarter of Fiscal year 2017 - Ergoresearch reports its results for the quarter ended December 31, 2016
6.22 Feb 23, 2017: LivaNova Announces Its Intent to Delist from London Stock Exchange
6.23 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016
6.24 Jan 04, 2017: SetPoint Medical Presents Positive Results In Ongoing Crohn’s Disease Study
6.25 Nov 28, 2016: Results for the first quarter of Fiscal year 2017 - Ergoresearch reports its results for the quarter ended
6.26 Nov 28, 2016: Ergoresearch reports its results for the quarter ended September 30, 2016
6.27 Nov 14, 2016: Mount Sinai Beth Israel Receive Award from The United States Department of Defense to Study Gulf War Illness with electroCore’s non-invasive vagus nerve stimulation therapy
6.28 Nov 10, 2016: VNS Therapy is Proven Treatment Option, but Treatment Gap Remains
6.29 Nov 02, 2016: LivaNova Announces CEO Transition: Damien McDonald to Succeed Andre-Michel Ballester
6.30 Nov 02, 2016: LivaNova Reports Third Quarter 2016 Results
6.31 Oct 28, 2016: Results for the fourth quarter and the fiscal year ended June 30, 2016 - Ergoresearch reports its 2016 annual results
6.32 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016
6.33 Oct 19, 2016: SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease
6.34 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results
6.35 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
6.36 Sep 29, 2016: LivaNova Announces Half-Year Financial Report
7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Vagus Nerve Stimulators - Pipeline Products by Stage of Development
Table 2: Vagus Nerve Stimulators - Pipeline Products by Territory
Table 3: Vagus Nerve Stimulators - Pipeline Products by Regulatory Path
Table 4: Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date
Table 5: Vagus Nerve Stimulators - Ongoing Clinical Trials
Table 6: Vagus Nerve Stimulators Companies - Pipeline Products by Stage of Development
Table 7: Vagus Nerve Stimulators - Pipeline Products by Stage of Development
Table 8: BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview
Table 9: CardioFit System - Product Status
Table 10: CardioFit System - Product Description
Table 11: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 12: AMT System - Product Status
Table 13: AMT System - Product Description
Table 14: Vagal Nerve Stimulator - Product Status
Table 15: Vagal Nerve Stimulator - Product Description
Table 16: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 17: Vagal Nerve Stimulator - Neural Cardiac Therapy for Heart Failure Study
Table 18: CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 19: t-VNS - Dementia - Product Status
Table 20: t-VNS - Dementia - Product Description
Table 21: Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 22: FitNes System - Alzheimer’s Disease - Product Status
Table 23: FitNes System - Alzheimer’s Disease - Product Description
Table 24: Cyberonics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 25: Nerve Wrap - Product Status
Table 26: Nerve Wrap - Product Description
Table 27: DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Intraluminal Implantable Device - Product Status
Table 29: Intraluminal Implantable Device - Product Description
Table 30: ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 31: GammaCore - Medication Overuse Headache - Product Status
Table 32: GammaCore - Medication Overuse Headache - Product Description
Table 33: GammaCore - Migraine - Product Status
Table 34: GammaCore - Migraine - Product Description
Table 35: Resolve Stimulator - Product Status
Table 36: Resolve Stimulator - Product Description
Table 37: ElectroCore, LLC - Ongoing Clinical Trials Overview
Table 38: GammaCore - Migraine - A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled Study of gammaCore Non-invasive Vagus Nerve Stimulator (nVNS) for the Acute Treatment of Migraine
Table 39: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview
Table 40: Aspire NP - Product Status
Table 41: Aspire NP - Product Description
Table 42: Centro Generator - Product Status
Table 43: Centro Generator - Product Description
Table 44: CentroSR Generator - Product Status
Table 45: CentroSR Generator - Product Description
Table 46: Equilia - Product Status
Table 47: Equilia - Product Description
Table 48: Griffin - Pulse Generator - Product Status
Table 49: Griffin - Pulse Generator - Product Description
Table 50: Intense Neuromodulation - Heart Failure - Product Status
Table 51: Intense Neuromodulation - Heart Failure - Product Description
Table 52: PhoenixRF SR - Product Status
Table 53: PhoenixRF SR - Product Description
Table 54: VITARIA System - Chronic Heart Failure - Product Status
Table 55: VITARIA System - Chronic Heart Failure - Product Description
Table 56: LivaNova PLC - Ongoing Clinical Trials Overview
Table 57: Equilia - Vagal Nerve Stimulation: Safe-guarding Heart Failure Patients (VANGUARD)
Table 58: Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview
Table 59: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Status
Table 60: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Description
Table 61: MicroTransponder Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 62: SAINT System - Anxiety Disorders - Product Status
Table 63: SAINT System - Anxiety Disorders - Product Description
Table 64: SAINT System - Tinnitus - Product Status
Table 65: SAINT System - Tinnitus - Product Description
Table 66: Serenity System - Tinnitus - Product Status
Table 67: Serenity System - Tinnitus - Product Description
Table 68: Vivistim Device - Product Status
Table 69: Vivistim Device - Product Description
Table 70: MicroTransponder Inc - Ongoing Clinical Trials Overview
Table 71: Vivistim Device - A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function after Stroke: VNS-REHAB
Table 72: Vivistim Device - A Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function after Stroke (MicroTransponder's Vivistim System) - Study MT-St-02 - Stroke
Table 73: Otto Bock HealthCare GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 74: Neuromodulation Device - Epilepsy - Product Status
Table 75: Neuromodulation Device - Epilepsy - Product Description
Table 76: Neuromodulation Device - Sleep Apnea - Product Status
Table 77: Neuromodulation Device - Sleep Apnea - Product Description
Table 78: Purdue University Pipeline Products & Ongoing Clinical Trials Overview
Table 79: Bionode Device - Product Status
Table 80: Bionode Device - Product Description
Table 81: Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 82: Implantable Neurostimulation Device - Rheumatoid Arthritis - Product Status
Table 83: Implantable Neurostimulation Device - Rheumatoid Arthritis - Product Description
Table 84: SetPoint Immune System Regulator - Crohn’s Disease - Product Status
Table 85: SetPoint Immune System Regulator - Crohn’s Disease - Product Description
Table 86: Setpoint Medical Corp - Ongoing Clinical Trials Overview
Table 87: SetPoint Immune System Regulator - Crohn’s Disease - Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-inflammatory Pathway Using a Vagal Nerve Stimulation Device in Patients with Active Refractory Crohn's Disease
Table 88: Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview
Table 89: Neurostimulation Device - Stroke Recovery - Product Status
Table 90: Neurostimulation Device - Stroke Recovery - Product Description
Table 91: Glossary

List of Figures
Figure 1: Vagus Nerve Stimulators - Pipeline Products by Stage of Development
Figure 2: Vagus Nerve Stimulators - Pipeline Products by Territory
Figure 3: Vagus Nerve Stimulators - Pipeline Products by Regulatory Path
Figure 4: Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date
Figure 5: Vagus Nerve Stimulators - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BioControl Medical
  • Boston Scientific Corp
  • CerboMed GmbH
  • Cerebral RX Ltd.
  • Cyberonics Inc
  • DuoCure Ltd.
  • ElectroCore, LLC
  • LivaNova PLC
  • Medical University of South Carolina
  • MicroTransponder Inc
  • Otto Bock HealthCare GmbH
  • Purdue University
  • Setpoint Medical Corp
  • Trifectas Medical Corp.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll